Abstract: The present disclosure relates to anticancer compounds, including, but not limited to, antibody-drug conjugates using the same, which compounds and ACDs thereof are suitable for the treatment of cancer.

Abstract: Disclosed are compounds of Formula (I): or stereoisomers, tautomers, or salts thereof, wherein each R is independently H or D. Also disclosed are methods of using such compounds to decrease the levels of IKZF1-4 proteins, and pharmaceutical compositions comprising the compound. The compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Abstract: Octaaminonaphthalene and a method of synthesizing octaaminonaphthalene are described. A two-dimensional coordination polymer and a method of synthesizing the two-dimensional coordination polymer are described. The two-dimensional coordination polymer includes ligands including anchorage sites, and metal linkers, each metal linker including a metal and an organic moiety. Each metal linker is coupled to two ligands via the anchorage sites. Synthesizing the two-dimensional coordination polymer includes contacting a first liquid precursor with a second liquid precursor at an interface, reacting the metal linker and the water-soluble ligand to yield a two-dimensional coordination polymer at the interface, and removing the two-dimensional coordination polymer from the interface.

Abstract: Provided are antibodies and fragments thereof having binding specificity to the claudin 6 (CLDN6) protein as well as their derivatives and uses.

Abstract: Provided are bispecific or multispecific antibodies that include an anti-CEACAM5 portion and one or more anti-4-1BB nanobodies whose agonist activity is dependent on the presence of the CEACAM5 antigen. Such bispecific or multispecific antibodies are safe, and are efficacious in treating cancer and have long-term protective immunological memory against tumors. Methods of using the antibodies for treating diseases such as cancer are also provided.

Abstract: An epitaxial wafer structure, an epitaxial function device, and manufacturing methods thereof are provided in the present disclosure. The epitaxial wafer structure is configured to be bonded to a driver substrate provided with a plurality of driver units including a plurality of non-defective driver units and a plurality of defective driver units. The epitaxial wafer structure includes a carrier substrate, a plurality of functional units disposed on the carrier substrate, and a plurality of placeholder units disposed on the carrier substrate. Each of the plurality of functional units on the carrier substrate is corresponding in position to one of the plurality of non-defective driver units on the driver substrate. Each of the plurality of placeholder units on the carrier substrate is corresponding in position to one of the plurality of defective driver units on the driver substrate.

Abstract: Provided are bispecific antibodies capable of binding to human VEGF protein and human PD-1 protein. These bispecific antibodies are effective in treating cancer.

Abstract: Provided are antibodies and fragments thereof having binding specificity to the liver receptor homolog 1 (LIV-1. SLC39A6 or ZIP6) protein as well as their derivatives and uses.

Abstract: Provided are antibodies and fragments thereof having binding specificity to the claudin 6 (CLDN6) protein as well as their derivatives and uses.

Abstract: Computerized systems and methods for segment based approach to routing picking are disclosed. The systems and methods may include performing steps for: receiving a floorplan of a first set of location IDs, wherein the first set of location IDs correspond to locations of multiple inventory items arranged in a floor; generating one or more base segments that connect the first set of location IDs; generating one or more route segments by combining the one or more base segments with one or more demand points corresponding to a second set of location IDs; generating one or more dispatch routes through the one or more route segments based on an optimal routing of resources that maximizes a density metric of the multiple inventory items included in the one or more dispatch routes; and assigning a first user to a combination of the one or more dispatch routes.

Abstract: Provided are antibodies and fragments thereof having binding specificity to the liver receptor homolog 1 (LIV-1, SLC39A6 or ZIP6) protein as well as their derivatives and uses.

Abstract: The present disclosure relates to KRAS inhibitors. Methods of treating cancers using the compounds are also provided.

Abstract: Provided are antibodies and fragments thereof having binding specificity to the claudin 6 (CLDN6) protein as well as their derivatives and uses.

Abstract: Provided are bispecific or multispecific antibodies that include an anti-CEACAM5 portion and one or more anti-4-1BB nanobodies whose agonist activity is dependent on the presence of the CEACAM5 antigen. Such bispecific or multispecific antibodies are safe, and are efficacious in treating cancer and have long-term protective immunological memory against tumors. Methods of using the antibodies for treating diseases such as cancer are also provided.

Abstract: The present disclosure relates to anticancer compounds, including, but not limited to, antibody-drug conjugates using the same, which compounds and ACDs thereof are suitable for the treatment of cancer.

Abstract: The present disclosure relates to KRAS inhibitors. Methods of treatment cancers using the compounds are also provided.

Abstract: Provided are antibodies and fragments having binding specificity to the signal regulatory protein alpha (SIRP?) protein and to the programmed death-ligand 1 (PD-L1) protein. The antibodies and fragments can bring peripheral macrophages to PD-L1+ tumor site, thereby enhancing tumor treatment.

Abstract: The present invention provides a programmed cell necrosis inhibitor, a preparation method therefor, and a use thereof. Specifically, the present invention provides a compound, or a pharmaceutically acceptable salt, hydrate, or solvent thereof, wherein the compound is as represented by formula I. The present invention further provides a preparation method for the compound and a pharmaceutical composition containing same, or a use of the compound in treatment or prevention of diseases or disorders related to programmed cell necrosis and/or human receptor interacting protein kinase 1 (RIPK1).

Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.